There were no significant differences in immune cell proportions between HD and untreated patients, while patients with current or previous chemotherapy/CDKi therapy had lower CD4+ T cell and pDC levels, as well as a higher percentage of monocytes (Fig. 1f). This evidence concerns the gene CD4 and Huntington disease.